The prospect of deep Medicaid cuts has become a flashpoint in Congress, with leaders of both parties accusing their counterparts of lying.

Although the tilsotolimod plus ipilimumab treatment did not meet its co-primary endpoint, these results are a valuable addition to the literature with respect to second-line treatment options in this ...

NCI employees received internal guidance last week to flag manuscripts, presentations, or other communications for scrutiny if they addressed “controversial, high profile, or sensitive” topics.

(HealthDay News) — Seventeen percent of American adults surveyed said they want to see Medicaid funding decreased, while 42% said funding should increase, and 40% said it should be kept about the same ...

Robert F. Kennedy Jr. is taking steps to tighten oversight of chemicals in the US food supply, a key component of his “Make America Healthy Again” agenda.

(HealthDay News) — A group of former US Centers for Disease Control and Prevention (CDC) employees is fighting to get their jobs back after being abruptly laid off last month.

The findings suggest that enfortumab vedotin, especially combined with pembrolizumab, offers promising beneficial outcomes in metastatic urothelial carcinoma treatment,” researchers wrote.

The volume of patient-initiated EHR messages “increased dramatically” after the onset of the COVID-19 pandemic and remained elevated through 2022, said A. Jay Holmgren, PhD.

From 1990 to 2023, there was a decrease in the number of births, general fertility rates, and total fertility rates in the United States.

In Virginia, Gov. Glenn Youngkin, a Republican, launched the Virginia Has Jobs program — a website designed to help laid-off federal workers quickly connect with available state jobs.

Phase 2 trial results support further development of neoadjuvant nivolumab-based CIT and adaptive de-escalation of CRT in patients with locoregionally advanced HNSCC, according to researchers.

Taxane chemotherapy is unable to sensitize prostate cancer to immune checkpoint inhibitors, resulting in another negative trial with immunotherapy in prostate cancer,” said Andrea Necchi, MD.